Delving into the Latest Updates on Lobaplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors), DNA alkylating agents

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases+ [3]

Active Indication

Breast CancerLeukemiaSmall Cell Lung Cancer+ [2]

Inactive Indication-

Originator Organization-

Active Organization

Hainan Chang'an International Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC9H18N2O3Pt

InChIKeyRLXPIABKJFUYFG-UHFFFAOYSA-M

CAS Registry135558-11-1

The goal of this prospective, open-label, single-center clinical study is to learn about the efficacy and safety of aderbelimab combined with chemotherapy in the perioperative treatment of esophageal and esophagogastric junction cancer. The main question it aims to answer are:prediction for pCR after perioperative adebrelimab and chemotherapy in esophageal and esophagogastric junction carcinoma

Start Date30 Mar 2024

Sponsor / Collaborator

Xijing Hospital

100 Clinical Results associated with Lobaplatin

Login to view more data

100 Translational Medicine associated with Lobaplatin

Login to view more data

100 Patents (Medical) associated with Lobaplatin

Login to view more data

211

Literatures (Medical) associated with Lobaplatin

31 Dec 2024·Annals of Medicine

Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma

Article

Author: Zhou, Ping ; Yu, Yi-Feng ; Wu, San-Gang ; Zhou, Rui ; Lin, Qin

BACKGROUNDThe therapeutic benefit of concurrent chemoradiotherapy (CCRT) in elderly nasopharyngeal carcinoma (NPC) patients remains controversial. This study aimed to investigate the efficacy and toxicity of lobaplatin-based CCRT in elderly patients with NPC.METHODSWe included stage II-IVA NPC patients aged ≥65 years who received lobaplatin concomitant with intensity-modulated radiation therapy (IMRT) between March 2019 and January 2023. Objective response rates and treatment-related toxicity were assessed. Kaplan-Meier's analysis was performed to calculate survival rates.RESULTSA total of 29 patients were included with a median age of 67 years. There were 19 patients (65.5%) who had comorbidities. All patients had serum EBV-DNA detective before treatment; the median EBV-DNA load was 236 IU/mL. There were 25 (86.2%) patients treated with induction chemotherapy, and the overall response rate was 92.0%. All patients received IMRT and concurrent chemotherapy with lobaplatin. During the CCRT, the most common adverse effect was haematological toxicity. Three patients (10.3%) had grade 3 leucopenia, three patients (10.3%) had grade 3 neutropenia, and eight patients (27.6%) had grade 3-4 thrombocytopenia. The rate of grade 3 mucositis was 34.5%. No patients had liver and kidney dysfunction. The median weight loss was 4 kg during CCRT. After three months of CCRT, the total response rate was 100%. EBV-DNA was not detected in any patients. The median follow-up was 32.1 months. The 3-year locoregional recurrence-free survival, distant metastasis-free survival, progression-free survival and overall survival were 95.8%, 85.7%, 82.5% and 100%, respectively.CONCLUSIONSLobaplatin-based CCRT is safe and feasible for elderly NPC patients, with satisfactory short-term survival outcomes and acceptable toxicities. A phase 2 trial is ongoing to investigate the role of lobaplatin-based CCRT on long-term survival and treatment toxicities for this population.

01 Nov 2024·Asian Journal of Surgery

The safety and effectiveness of prophylactic hyperthermic intraperitoneal chemotherapy in patients with pathological T3-4 locally advanced colon cancer

Article

Author: Zhang, Zongjin ; Xian, Zhenyu ; Xiang, Haidong ; Mo, Taiwei ; Shi, Yaqian ; He, Xiaowen ; Chen, Yongle ; Wen, Xiaofeng ; Huang, Junhua ; Hu, Tuo

INTRODUCTIONThe safety and effectiveness of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in pathological T3-4 locally advanced (pT3N + M0 and pT4NxM0) colon cancer (CC) patients with radical resection need further study.METHODSClinical and pathological information of pT3-4 locally advanced CC patients who received radical surgery in our hospital from January 2018 to December 2020 were analyzed. The prognosis of patients was estimated using Cox proportional hazards regression analysis and Kaplan-Meier method.RESULTSAmong 927 patients, 10.4% (96/927) received prophylactic HIPEC based on 5-FU, 4.6% (43/927) received prophylactic HIPEC based on lobaplatin, 85.0% (788/927) received conventional therapy. The incidence of metachronous peritoneal carcinomatosis (mPC) was 9.4%. Complications occurred in 32 patients (4.1%) in the conventional therapy group, 6 patients (6.3%) in the prophylactic HIPEC group based on 5-FU and 3 patients (7.0%) in the prophylactic HIPEC group based on lobaplatin within 30 days after surgery (5-FU vs. conventional therapy group, p = 0.464; Lobaplatin vs. conventional therapy group, p = 0.591). Multivariate Cox regression analysis revealed that prophylactic HIPEC based on either 5-FU or lobaplatin regimen could not effectively improve mPC-free survival (5-FU: p = 0.020, HR = 1.927, 95% CI, 1.111-3.343; Lobaplatin: p = 0.167, HR = 0.247, 95% CI, 0.034-1.796), overall survival (5-FU: p = 0.361, HR = 1.360, 95% CI, 0.703-2.634; Lobaplatin: p = 0.780, HR = 0.816, 95% CI, 0.195-3.416) and disease-free survival (5-FU: p = 0.525, HR = 1.149, 95% CI, 0.749-1.760; Lobaplatin: p = 0.117, HR = 0.488, 95% CI, 0.199-1.198).CONCLUSIONEarly prophylactic HIPEC based on 5-FU or lobaplatin subsequent to radical resection for patients with pT3-4 locally advanced CC is safe, but not effective in reducing the risk for mPC.

01 Jul 2024·Asian Pacific Journal of Cancer Prevention

Intraperitoneal Irrigation Chemotherapy with Lobaplatin in Locally Advanced Gastric Cancer: A Special Type of Abdominal Chemotherapy

Article

Author: Zhong, Yuxin ; Zhang, Jing ; Sun, Yuemin ; Wang, Peng ; Bai, Xiaofeng

BACKGROUNDThis study evaluated the safety and efficiency of intraperitoneal irrigation chemotherapy with lobaplatin for the treatment of advanced gastric cancer (GC).METHODSA total of 56 locally advanced GC patients (experimental group) who received intraoperative intraperitoneal irrigation chemotherapy in addition to undergoing radical D2 surgery were matched 1:1 based on 8 covariates to 56 patients without drug treatment (control group). Clinical data were collected and analyzed.RESULTThe two groups were well balanced in basic characteristics and had comparable clinical indices. All patients had similar time to first flatus (2.8 ± 0.3 vs. 2.9 ± 0.3 d, P = 0.076), time to first oral intake (3.5 ± 3.4 vs. 4.1 ± 4.6 d, P = 0.439), and duration of postoperative hospitalization (9.1 ± 3.2 vs. 9.6 ± 4.0 d, P = 0.446). There were no significant differences in postoperative complications including anastomotic and duodenal stump leakage, abdominal and anastomotic bleeding, seroperitoneum, and incision infection between the experimental and control groups (P > 0.05). The rates of chemotherapy-related side effects including allergic reaction, neurotoxicity, diarrhea, and nausea/vomiting were also similar between the two groups, and there were no abnormalities in leukocyte and platelet levels and liver and renal function during the first 5 days after surgery.CONCLUSIONIntraperitoneal irrigation chemotherapy with lobaplatin is safe for patients with advanced gastric cancer.

100 Deals associated with Lobaplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XA	DB13049

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	-
Leukemia	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	-
Small Cell Lung Cancer	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Epithelial Carcinoma	Phase 2	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	30 May 2018
Platinum-sensitive epithelial ovarian cancer	Phase 2	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	30 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2100043027 (neoALTAL, ESMO2023) Manual	Phase 2	Triple Negative Breast Cancer Neoadjuvant	45	Anlotinib + docetaxel+nab-paclitaxel + lobaplatin	(zzeanlgzty) = srhzqhkeid ftimzvctcc (adiresxwnz, 42.2 - 72.3) View more	Positive	21 Oct 2023
				Anlotinib + docetaxel+nab-paclitaxel + lobaplatin (IM subtype)	(zzeanlgzty) = osscuwvutq ftimzvctcc (adiresxwnz )
ChiCTR-TRC-14005019 (ASCO2023)	Phase 1	Triple Negative Breast Cancer Neoadjuvant	-	lobaplatin (High PLR)	fvbhncqxut(wxptmpirjn) = rmxyklhspl qmxoomzhzm (zngycrnlsl )	Positive	31 May 2023
				lobaplatin (Low PLR)	fvbhncqxut(wxptmpirjn) = lwkzspwsle qmxoomzhzm (zngycrnlsl )
ASCO2023	Not Applicable	Nasopharyngeal Carcinoma Neoadjuvant	44	Tislelizumab and GP regimen	qozadoccyn(fqdnhqfxdd) = Grade 3-4 irAEs were rash(2) and hypothyroidism(1) ptxziffrtk (myncuzuopu )	Positive	31 May 2023
				Chemoradiotherapy including IMRT, lobaplatin and nimotuzumab
Pubmed Manual	Not Applicable	Non-squamous non-small cell lung cancer Second line	126	Lobaplatin+Albumin-Bound Paclitaxel+Bevacizumab	(ibtwyhhmgx) = hojczxdczg xdizcwkvcs (nefatqvyfo, 5.86 - 6.56) View more	Positive	26 Jun 2022
				Lobaplatin+Albumin-Bound Paclitaxel	(ibtwyhhmgx) = vtouabqmgj xdizcwkvcs (nefatqvyfo, 4.956 - 5.191) View more
NCT03057106 (CCTG BR34 \| CCTG BR.34, CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	301	Tremelimumab+Durvalumab (Durvalumab and Tremelimumab)	(trucbmichw) = fstujqvysh iiavdlgmvw (clnsorzkam, eqakomqyom - iyzpzffthr) View more	-	09 Feb 2022
				Tremelimumab+Lobaplatin+Cisplatin,+Durvalumab+Nedaplatin (Platinum Based Chemotherapy + Durvalumab + Tremelimumab)	(trucbmichw) = osrosbmoev iiavdlgmvw (clnsorzkam, ukeimzombl - vkqlwgljyv) View more
NCT03413436 (Pubmed \| Front Oncol)	Phase 4	Esophageal Carcinoma Adjuvant	733	Lobaplatin plus docetaxel	jyprftzbde(ilvxoejuqu) = lkwulbhbzp asgzagkuhk (oacvvyknku ) View more	-	01 Jan 2021
				Cisplatin plus docetaxelCisplatin plus docetaxel	jyprftzbde(ilvxoejuqu) = fbpglpagfh asgzagkuhk (oacvvyknku ) View more
CSCO2020	Not Applicable	Uterine Cervical Cancer	90	白蛋白紫杉醇联合洛铂经介入栓塞给药化疗	mtudgjhznr(wvhwuzffgh) = dlpeglhaeo qwsghtcldu (zrvkgdemkt )	Positive	19 Sep 2020
CSCO2020	Phase 4	Metastatic breast cancer	1,181	Lobaplatin plus paclitaxel	(sicndhnwns) = ijmtnztpoe agyizyejbb (mrfkmrsbpl )	-	19 Sep 2020
NCT03188497 (Pubmed \| Transl Oncol)	Phase 1	Nasopharyngeal Carcinoma	17	Lobaplatin 25-50 mg/m2	(lqdwjgbesr) = ylttdayumd rciycahzgw (xegpvtzekr )	-	01 Aug 2018
ChiCTR-TRC-10001047 (ASCO2014)	Phase 3	Extensive stage Small Cell Lung Cancer First line	234	Lobaplatin/Etoposide	(mzbofespqt) = fgnnvqpdjx llxahddbzq (oidvyoutkt ) View more	-	20 May 2014
				Cisplatin/EtoposideCisplatin/Etoposide	(mzbofespqt) = agkmaggouv llxahddbzq (oidvyoutkt ) View more